CRS/ICANS (Neurotoxicity) Management Solution Design Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides a CRS/ICANS (Neurotoxicity) Management Solution Design Service to support the development of safer next-generation cell therapies and bispecific antibodies. This service addresses unpredictable neurotoxicity signals, limited sensitivity for early ICANS risk detection, and the challenge of balancing CAR-T potency with patient safety. Through high-resolution cytokine profiling, advanced 3D blood-brain barrier modeling, and single-cell neuroimmune transcriptomic analysis, our solution delivers actionable mechanistic insights. Creative Biolabs enables streamlined studies and optimized clinical safety protocols, helping sponsors systematically de-risk neurotoxicity liabilities across the entire immunotherapy development pipeline.

Introduction

ICANS remains a significant challenge in cellular immunotherapy, often occurring independently of systemic CRS. Current research emphasizes that while T-cell activation initiates the process, monocyte-derived cytokines are the primary drivers of blood-brain barrier disruption and subsequent neuroinflammation. By integrating human-relevant 3D models and high-sensitivity multiplexed assays, Creative Biolabs provides a predictive framework. Our solutions bridge the gap between benchtop engineering and clinical safety, ensuring robust therapeutic outcomes.

Pathological process of CRS induced by CAR-T cell therapy. (OA Literature) Fig.1 The pathological process of CRS following CAR-T cell therapy.¹

How Creative Biolabs' CRS/ICANS Management Solution Design Can Assist Your Project

Creative Biolabs provides a comprehensive suite of deliverables aimed at identifying the precise triggers of immune-mediated neurotoxicity. By utilizing human-relevant primary cell models and advanced bioassays, we deliver actionable data that allows you to modify drug designs, such as tuning costimulatory domains or integrating safety switches, long before clinical exposure. Our solutions help you define the therapeutic index, characterize dose-response kinetics, and establish clear safety monitoring thresholds for regulatory submission.

Discover how we can help. Request a consultation today.

What We Can Offer

We provide design solutions built on proven clinical frameworks and research insights for CRS/ICANS management:

Risk Assessment & Monitoring Design: Define biomarker panels and early warning systems.
Toxicity Intervention Algorithms: Draft grade-based intervention pathways incorporating cytokine antagonists and supportive care.
Neurotoxicity Grading & Response Plans: Incorporate standardized neurologic scoring and intervention triggers.
Adaptive Strategy Workshops: Align safety planning with sponsor workflows and clinical development timelines.

Our Workflow

The workflow is designed to be a data-driven journey from construct intake to a finalized safety management report, ensuring every aspect of neuroinflammation is quantified.

Required Starting Materials: To initiate the service, clients typically provide the Vector map or plasmid of the CAR construct, specific scFv sequence data, and the expected therapeutic concentration range based on preliminary efficacy data.

Workflow of CRS/ICANS Management Solution Design. (Creative Biolabs Original)

Benefits

Chimeric Cytokine Receptor Engineering: Implementation of switchable or "logic-gated" cytokine receptors to modulate T-cell activity in response to the microenvironment;
Customized Toxicity Mitigation Strategies: Design of proprietary safety switches tailored to your specific CAR construct;
Precision scFv & Domain Optimization: Modification of costimulatory domains and linker lengths to fine-tune the activation threshold;
Cross-Platform Compatibility: Service application across various cell types, including αβ T cells, γδ T cells, NK cells, and Macrophages.

FAQs

Q1: Can you evaluate solid tumor CAR-T targets for neurotoxicity?

A1: Yes, our platform is adaptable to any target, including solid tumor antigens where off-tumor/on-target CNS expression is a concern. We tailor the co-culture models to suit your specific indication.

Q2: How does your in vitro BBB model compare to animal models?

A2: Our human-derived 3D BBB model provides higher translational fidelity for human-specific cytokine receptors and barrier functions, which are often absent or different in murine models.

Q3: Is it possible to include specific cytokines in the panel?

A3: Absolutely. While we focus on the core "ICANS signature," we offer custom panels of over 200 analytes to match the unique mechanism of action of your therapeutic.

Q4: How do I know which management strategy is right for my construct?

A4: Our scientific team provides expert interpretation of all data, recommending specific mitigation designs like cytokine filters or safety switches based on the observed risk profile.

Partner with Us

At the forefront of immunotoxicity innovation, Creative Biolabs utilizes proprietary 3D CNS platforms to transcend the limitations of conventional animal testing. Our unique methodology combines single-cell transcriptomics with functional neuroimmune profiling, offering an unparalleled perspective on ICANS pathogenesis. We specialize in the end-to-end design and validation of toxicity management solutions, ensuring safety is built into your immunotherapy's DNA from day one. Partner with us to transform complex neurotoxicity challenges into evidence-based design successes.

For more information, technical support, or to request a customized project proposal, please contact us. We are dedicated to accelerating your drug discovery journey with precision and expertise.

Reference

Zhang, Yajing, and Weidong Han. "Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review." Clinical Cancer Bulletin, vol. 4, 5, 1 July 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1007/s44272-025-00044-0

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.